Optima IPL Receives CFDA Mark Approval for Treatment of Dry Eye Disease Now this exciting technology is available to practitioners in China for DED
Lumenis Announces a Breakthrough in Aesthetic Medical Devices: NuEra® Tight with FocalRF® Technology
Lumenis Ltd., the world’s largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, is proud to announce its latest innovation, the NuEra Tight with FocalRF technology. The platform introduces a breakthrough in personalized non-invasive RF body treatments to match the unique needs of every patient
A new collaboration with the Harrods Wellness Clinic in London, establishing a partnership of excellence
Lumenis is proud to announce a new partnership with the prestigious Harrods Wellness Clinic, London, UK. Harrods will equip its aesthetic clinic with the Stellar M22™.
SmoothGlo
SmoothGlo is an innovative sequential skin treatment that utilizes two proven technologies delivered one following the other in one session that results in visibly fuller, brighter, firmer, and more youthful looking skin.
FDA approves IPL device to manage dry eye disease
Patented Lumenis Optimal Pulse Technology (OPT) becomes the first IPL approved for management of dry eye disease due to MGD, and Lumenis launches OptiLight.
Ge et al. (2020): Evaluation of the efficacy of optimal pulsed technology treatment in patients with cataract and Meibomian gland dysfunction in the perioperative period
In a prospective, comparative study, Lumenis IPL with OPT™ improved signs and symptoms of mild to moderate MGD in patients who underwent cataract surgery.
Lumenis Disrupts the Energy-Based Treatment Category with a New Facial Stimulation Treatment, triLift™
Lumenis Be, Ltd., a leading energy-based medical device company for aesthetic and eye care applications, is proud to announce the launch of triLift, a facial stimulation device targeting the three aging elements: structure, contour, and texture, by treating the three tissue layers – the muscles, the dermal layer and the epidermal layer. Lumenis is proud to unveil this new device exclusively at the 2022 AAD Annual Meeting’s show floor from March 25th – March 27th.
Baring Private Equity Asia Announces Agreement to Sell Lumenis’ Surgical Business to Boston Scientific for $1.07 bln
Baring Private Equity Asia (BPEA) and Lumenis announced today that they have entered into a definitive agreement to sell the Lumenis Surgical Business to Boston Scientific (NYSE: BSX) in a transaction valued at USD1.07 billion, subject to closing adjustments.
Baring Private Equity Asia Agrees to Acquire Lumenis
“Baring Private Equity Asia today announced that its affiliated private equity funds (“BPEA”) have agreed to acquire Lumenis”
Lumenis and Baring Private Equity Asia to Accelerate Investment in Aesthetics and Vision Verticals Following the Strategic Sale of Lumenis Surgical for $1.07B
Lumenis will refocus and accelerate planned investments to support the development of its fast-growing Aesthetic and Vision businesses, emphasizing R&D, global sales and marketing channels, and business development activities.